{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:43:38Z","timestamp":1768545818276,"version":"3.49.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:p><jats:bold>INTRODUCTION:<\/jats:bold> Patients with isoniazid (H, INH) resistant pulmonary TB but undetected rifampicin (R, RIF) resistance are treated with a 6-month regimen of levofloxacin-RIF-ethambutol-pyrazinamide (6LvxREZ) under India\u00b4s National TB Elimination Programme (NTEP).<jats:bold>OBJECTIVE:<\/jats:bold>\n To describe the profile of and treatment outcomes in patients with pulmonary INH-resistant (INH<jats:sup>R<\/jats:sup>) TB initiated on TB treatment, and identify factors associated with unfavourable treatment outcomes (died, failed, treatment changed, lost to follow-up).<jats:bold>METHODS:<\/jats:bold> This was\n a retrospective analysis of NTEP database (Ni-kshay) on pulmonary INH<jats:sup>R<\/jats:sup> TB patients initiated on treatment with \u201cH mono\/poly regimen\u201d (6LvxREZ) between July 2019 and June 2020 with documented treatment outcomes. Proportions with 95% confidence interval (CI) was calculated\n and logistic regression analysis was performed.<jats:bold>RESULTS:<\/jats:bold> Of the 11,519 patients with pulmonary INH<jats:sup>R<\/jats:sup> TB, 9,440 (82%) had treatment success (55.1% cured, 26.9% treatment completed). Unfavourable treatment outcome was observed in 1,901 (16.5%). Male sex, tobacco and alcohol\n use, HIV reactive status were associated with unfavourable treatment outcome. Patients with <jats:italic>kat<\/jats:italic>G mutations and resistance to fluoroquinolones were likely to have poor treatment outcomes.<jats:bold>CONCLUSION:<\/jats:bold> A levofloxacin-based regimen offers a treatment success rate of 82% in patients\n with pulmonary INH<jats:sup>R<\/jats:sup> TB. Sex-specific strategies, interventions to address smoking and alcohol use, focus on HIV-reactive patients and optimising treatment regimens based on drug susceptibility should be considered for improving treatment outcomes.<\/jats:p>","DOI":"10.5588\/ijtld.21.0701","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T04:34:14Z","timestamp":1666672454000},"page":"1033-1040","source":"Crossref","is-referenced-by-count":5,"title":["Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB"],"prefix":"10.5588","volume":"26","author":[{"given":"B.","family":"Velayutham","sequence":"first","affiliation":[{"name":"Indian Council of Medical Research-National Institute for Research in Tuberculosis, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Shah","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health and Family Welfare, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Mythily","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research-National Institute for Research in Tuberculosis, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gopalaswamy","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research-National Institute for Research in Tuberculosis, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health and Family Welfare, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mandal","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health and Family Welfare, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Parmar","sequence":"additional","affiliation":[{"name":"Country Office, World Health Organisation, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Padmapriyadarsini","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research-National Institute for Research in Tuberculosis, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2022\/00000026\/00000011\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:35:08Z","timestamp":1666758908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.21.0701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"alternative-id":["1027-3719(20221101)26:11L.1033;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.21.0701","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}